GlobeNewswire

NuVinci® Cycling Embarks on Next Chapter - With New Division Name 'enviolo'

Dela

 

Stepless and automatic shifting company aims to become 'The Moving Standard' for bicycles and e-bikes today.

AMSTERDAM, NETHERLANDS / CEDAR PARK, TEXAS, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Beginning January 1, 2018, NuVinci Cycling, a division of Fallbrook Technologies Inc. (Fallbrook), will be operating under a new name: enviolo.

The purpose for rebranding NuVinci Cycling is to celebrate the division's success and growth story, while marking the start of its next chapter. The division will be operating more independently from its parent company, Fallbrook, to ensure a complete focus on the bicycle market. 

"Our journey since 2007 has been incredible! Our stepless and automatic products has captured OEMs, dealers, and consumers by offering a riding experience like no other. We have grown into a very relevant business with many more opportunities to explore. Now, we are ready to embark on our next chapter - as enviolo" says David Hancock, Managing Director of NuVinci Cycling.

enviolo's stepless and automatic shifting solutions have one very essential ingredient: the revolutionary NuVinci® technology from Fallbrook. This technology is responsible for the unique smooth, stepless shifting, and overall riding experience. Fallbrook's NuVinci technology has also been licensed to other companies and is currently in commercial development for automotive applications, scooters, micro-mobility solutions, and off-road utility vehicles. The new division name aims to better differentiate between the technology brand, NuVinci by Fallbrook, and the products utilizing that technology, now offered by enviolo. Starting with MY2019 groupsets, enviolo will also use the new brand name in the product names.

"enviolo is not just about a new name and logo: the division's next chapter, marked by the new name, is going to bring a great deal of additional value to manufacturers, dealers, and consumers. We aim to become the 'The Moving Standard' for bicycles and e-bikes today - with a new, needs-based product portfolio, increased service capabilities, retailer support programs, and direct-to-consumer marketing initiatives," summarizes Anne Guethoff, Marketing Director at NuVinci Cycling and responsible for the brand strategy development and execution. "We have built a business that is ready for the next stage of growth, and that includes scaling up our workforce and their skill sets. Our new name celebrates both our past success and the next chapter in our evolution," David Hancock adds. 

The division recently launched its new MY2019 product portfolio, which includes five new group sets designed specifically for the needs of the individual  rider and their respective bicycle use cases. With the new group sets for city, trekking, cargo, sportive, and commercial, enviolo is expanding the unique technology into additional segments. 

Furthermore, retailer support has been increased significantly across Germany, Austria, and Switzerland (DACH) as well as Belgium, the Netherlands, and Luxembourg (BENELUX) markets with the introduction of an extensive retailer training series, online training, and the recent launch of the exclusive "Experience Partner Program." 

The division is investing substantially in its service capability as well with new markets such as France, Switzerland, and Germany now being managed directly by the International Service Center in The Netherlands. New systems, tools, and processes are being implemented in service support to create a more effective process for partners.

Usage of the brand in the retail environment including new product training and more will commence in January 2018. MY2019 models will already feature the new enviolo-branded groupsets. End-consumers will engage with the new brand starting mid-2018. For additional information, please visit www.enviolo.com. 

About NuVinci® Cycling

N uVinci Cycling, a division of Fallbrook Technologies Inc., moves people better through its product portfolio of smooth, stepless, automatic, and integrated shifting products for bicycles and eBikes. The NuVinci technology incorporated in continuously variable transmissions (CVT) for bicycles has been providing the best rider experiences since 2006. NuVinci Optimized(TM) cycling products include the Nfinity(TM) and Harmony(TM) group sets, utilizing the latest versions of the transmissions and controllers. Products from NuVinci Cycling, the leader in CVTs for bikes and eBikes, are available globally in over 100 bicycle brands. For more information, visit www.nuvincicycling.com.  

About Fallbrook Technologies

Fallbrook Technologies is the inventor of the revolutionary NuVinci® continuously variable planetary (CVP) technology, which enables performance and efficiency improvements for machines that use an engine, pump, motor, or geared transmission system - including urban mobility vehicles, cars and trucks, industrial equipment, and many other applications. Fallbrook has a unique collective development model and community through which NuVinci technology licensees share enhancements, which adds to the value of the technology and accelerates product development. This approach enables forward-looking companies, who wish to create visionary new products with NuVinci technology, to move quickly from concept to market commercialization. Fallbrook is based in Cedar Park near Austin, Texas, USA and holds rights to over 800 patents and patent applications worldwide. For more information, visit www.fallbrooktech.com. 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af7b0064-add1-4bf8-89a9-d1f1a423a28b

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7516a904-b129-4bf3-a3be-3ff7858286a6

Anne Guethoff, Marketing Director
NuVinci® Cycling
+ 49 160 92290159
Anne.Guethoff@nuvincicycling.com

Trammie Anderson, Director of Corporate Marketing
Fallbrook Technologies Inc.
+1 512 519 5194
trammie.anderson@fallbrooktech.com
 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuVinci Cycling via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum